TrialAmerican journal of clinical dermatology2021

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.

Yan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.